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Background: Some children born small for gestational age (SGA) experience supra-physiological insulin-like 
growth factor-I (IGF-I) concentrations during GH treatment. However, measurements of total IGF-I 
concentrations may not reflect the bioactive fraction of IGF-I which reaches the IGF-I receptor at target organs. 
We examined endogenous IGF-bioactivity using an IGF-I kinase receptor activation (KIRA) assay that 
measures the ability of IGF-I to activate the IGF-IR in vitro.  
Aim: To compare responses of bioactive IGF and total IGF-I concentrations in short GH treated SGA children 
in the North European Small for Gestational Age Study (NESGAS).  
Material and method: In NESGAS, short SGA children (n=101, 61 males) received GH at 67µg/kg/day for 
1 year. IGF-I concentrations were measured by Immulite immunoassay and bioactive IGF by in-house KIRA 
assay. 
Results: Bioactive IGF increased with age in healthy pre-pubertal children (n=94). SGA children had low-
normal bioactive IGF levels at baseline (-0.12 (1.8 SD), increasing significantly after one year of high-dose 
GH treatment to 1.1 (1.4) SD, p<0.01. Following high-dose GH, 68% (n=65) of SGA children had a total IGF-
I concentration >2SD (mean IGF-I 2.8 SDS), whereas only 15% (n=15) had levels of bioactive IGF slightly 
above normal reference values. At baseline, bioactive IGF (SDS) was significantly correlated to height (SDS) 
(r=0.29, p=0.005), in contrast to IGF-I (SDS) (r=0.17, p=0.10). IGF-I (SDS) was inversely correlated to delta 
height (SDS) after one year of high-dose GH treatment (r=-0.22, p=0.02). 
Conclusion: In contrast to total IGF-I concentrations, bioactive IGF stayed within the normal reference 




























Despite supra-normal IGF-I concentrations, bioactive IGF stayed within the normal reference range for most 




























Insufficient catch-up growth in some children born small for gestational age (SGA) may result in a low final 
height. Growth hormone (GH) treatment has a well-documented overall beneficial effect on final height in 
children born SGA and was approved for treatment of SGA children with persistent short stature in the EU in 
2004 (1,2). Nevertheless, the growth response to GH treatment among SGA children is characterized by 
considerable variability (3), and some SGA children experience supra-physiological serum insulin-like growth 
factor-I (IGF-I) concentrations during treatment (4).  
 
Long-term safety and mortality in patients treated with GH during childhood is an ongoing concern, but the 
debate has been characterized by conflicting data. Studies in large epidemiological cohorts of healthy adults 
have shown an association between elevated IGF-I levels and an increased risk of cancer and all-cause 
mortality (5–7). However, no studies have been able to establish a link between elevated IGF-I levels during 
GH treatment in childhood and increased morbidity or mortality later in life. Though, there is still a need for 
follow-up studies of long-term risk of disease after GH treatment in childhood. In the majority of clinical 
guidelines for the approved indications of GH treatment in childhood (e.g. SGA, Turner Syndrome and Prader-
Willi Syndrome) it is recommended that serum IGF-I concentrations are kept within the normal reference 
range during GH treatment (2,8,9).   
 
In the bloodstream the majority of IGF-I circulates bound to IGF-binding proteins (IGFBPs) while 
approximately 1% circulates as unbound, free IGF-I (10). The IGFBPs, IGFBP-proteases (e.g. pregnancy 
associated plasma protein A and A2) as well as modifiers of IGFBP protease activity (e.g. stanniocalcin 1 and 
2) affect the interaction between IGF-I and its IGFBPs, and thereby alter the bioactivity of IGF-I (11). 
Measurements of the concentration of total IGF-I by immunoassay, whereby IGF-I is stripped from the 
IGFBPs, do not take the modifying effects of IGFBPs and IGFBP-proteases into account. Therefore, we used 
the IGF-I kinase receptor activation (KIRA) assay, as this determines the ability of serum IGF-I to 
phosphorylate and thereby activate the IGF-I receptor (IGF-IR) (12,13). We believe this gives a biologically 
relevant estimate of the ability of serum IGF-I to activate the IGF-IR, and hence IGF-bioactivity. Indeed, a 
discrepancy between bioactive and total levels of IGF-I has been reported in both adults (14) and children (15) 
and it was reported that in adults, bioactive IGF concentrations correlated better with the diagnosis of GH 
deficiency (GHD) than total IGF-I levels (16).  
 
In the current study we hypothesized that increased concentrations of IGF-I did not reflect the concentration 
of bioactive IGF. Accordingly, the aim of this study was to determine a normal reference range for bioactive 

























concentrations, respectively, with growth and metabolic responses in short GH treated SGA children in the 
North European Small for Gestational Age Study (NESGAS).  
 
MATERIALS AND METHODS 
Study population and design 
NESGAS is a multicenter, randomized, parallel group study (EudraCT2005-001507-19) of GH treatment in 
short pre-pubertal children born SGA. The study population and design has been described in detail in previous 
publications (15, 26-29). In brief, all children received a fixed dose of 67 µg/kg/day of recombinant human 
GH (Norditropin®, Novo Nordisk, Bagsværd, Denmark) given as a daily subcutaneous injection during the 
first year of therapy to induce catch-up growth and identify non-responders. Data regarding weight, height and 
IGF-I using the Immulite assay have previously been published (26). One hundred and one (61 males) children 
from the NESGAS study were included in the current study. Only data from study entry and during the first 
year of GH therapy were included. The NESGAS study was performed according to the Helsinki II declaration 
and approved by the Ethical Committee or Institutional review board and national drug authorities in each 
study center. Written informed consent was obtained from parents or guardians of each child participating in 
the NESGAS study.  
 
Laboratory measurements 
Serum IGF-I and IGFBP-3 concentrations were determined using a solid-phase enzyme-labelled 
chemiluminescent immunometric assay (Immulite 2000, Diagnostic Products Corporation, LA, USA). 
Standards were calibrated against the WHO NIBSC IRR 87/518.  The IGF-I detection limit was 20 ng/mL, 
inter-and intra-assay coefficients of variation (CVs) were 5.93% and 2.02%, respectively. The detection limit 
for IGFBP-3 was 500 ng/mL and inter-and intra-assay CVs were 5.23 % and 1.74 % respectively. IGF-I and 
IGFBP-3 SDS were calculated from our reference data based on serum samples from 1729 healthy children 
(911 girls) using the same assays (17,18).  
IGFBP-1 and bioactive IGF were measured by in-house assays at Medical Research Laboratories, Aarhus 
University Hospital, Denmark. IGFBP-1 was measured by an in-house time-resolved immunofluorometric 
assay (TR-IFMA), with intra- and inter-assay CVs of 5 and 10%, respectively (19). Bioactive IGF was 
measured using the IGF-I KIRA assay, as described by Chen et. al. (21) with modifications (19). The detection 
limit was 0.1 ng/mL, and the intra-assay CV of samples 12%. The long-term inter-assay CV of a control sample 
was 20%. Samples were analyzed against a serial dilution of the WHO IGF-I reference preparation 02/254, 
and results expressed in ng/mL. Care was taken to analyze samples from the same individual in the same assay 
run. Insulin has a negligible cross-reactivity, whereas IGF-II cross-reacts with 12% (12). To acknowledge this, 

























Reference range for bioactive IGF in a cohort of healthy children  
A subpopulation of 150 healthy children (75 males) aged 6 to 11 years from the COPENHAGEN Puberty 
Study (30, 31) were included. All children were healthy Caucasian, and prepubertal at evaluation. A single 
non-fasting blood sample was drawn from an antecubital vein between 8 and 12 o’clock. Blood was 
centrifuged and stored at -20 Celsius until analyses.  
 
Other Assays 
Plasma insulin and C-peptide levels were measured by a DELFIA assay using kits B080-101 and B081-101 
respectively (Perkin Elmer Life Sciences, Turku, Finland) as described in detail previously (4). Plasma glucose 
and HbA1c were measured locally employing assays routinely used for clinical purposes. 
 
Statistics 
Normal distributed data were presented as mean (SD), while non-normal distributed data were presented as 
median (interquartile range). Age and gender corrected SD-scores for IGF-I measured by Immulite were 
calculated from our reference data based on samples from 1,729 healthy children, as previously published 
(17,18). Age and gender corrected SD-scores for bioactive IGF were calculated using a normal reference 
population of 150 healthy children. Differences between the sexes were compared by independent sample t-
test or Mann-Whitney test and ANOVA test or Kruskal-Wallis test when appropriate. A correlation matrix 
was completed using Spearman non-parametric correlations. P-values <0.05 were considered significant. The 
statistical analyses were performed using statistical package PASW (version 22; SPSS Inc., Chicago, IL).  
 
RESULTS 
Baseline concentrations of bioactive IGF in short SGA children were within the normal range of healthy 
children (Table 1, Figure 1), although in the lower part of the reference ranges. Moreover, bioactive IGF  
concentrations at baseline were significantly lower in boys (-1.4 SDS (-2.7 to -0.2)) (median (25-75 percentile)) 
compared to girls (-0.2 SDS (-1.4 – 0.4)) (p=0.002) (Table 1, Figure 1). In contrast, there were no significant 
differences in total IGF-I concentrations (SDS), weight (SDS) or height (SDS) between boys and girls at 
baseline (Table 1).  
Bioactive IGF (SDS), weight (SDS) and height (SDS) did not differ between genders after one year of GH 
treatment (Table 1, Figure 1) and thereby a significantly greater change was found in bioactive IGF among 
boys (+2.7 SDS (1.2 – 4.6)) than girls (+1.2 SDS (0.5 – 1.6)) (p=0.004) after one year of GH treatment (Table 
1, Figure 2a). Changes in total IGF-I concentrations (SDS) (Figure 2b) and height (SDS) (Figure 2c) were 


























After one year of GH treatment only 15% (n=15) of the children in the NESGAS cohort had levels of bioactive 
IGF above 2 SD (figure 2a) whereas 68% (N=65) of the children had concentrations of total IGF-I (SDS) 
above the normal range (> 2SD) (Figure 2b).  
 
Bioactive IGF (SDS) correlated significantly with IGF-I (SDS) (r=0.35, p=0.001) and IGFBP-3 (SDS) (r=0.36, 
p=0.001) at baseline (table 2). Bioactive IGF (SDS) was significantly correlated with height (SDS) and weight 
(SDS) at baseline (table 2) but did not correlate to changes in height (SDS) after one year of GH treatment. In 
contrast, concentrations of IGF-I (SDS) and IGFBP-3 (SDS) were not associated with height (SDS) or weight 
(SDS) at baseline but correlated inversely with changes in height (SDS) after one year of treatment. Insulin 
sensitivity determined by HOMA-S were negatively correlated with bioactive IGF (r=-0.29, p=0.007), IGF-I 
(r=-0.27, p=0.01), IGFBP-3 (r=-0.33, p=0.005) and insulin secretion (r=-0.47, p<0.001). Furthermore, we 
observed a significant positive association between HOMA-S and IGFBP-1 as well as with change in height 
from baseline to 1 year (Table 2). IGFBP-1 was negatively correlated to delta height (SDS) after one year of 
high-dose GH treatment (Table 2). 
The change in bioactive IGF (SDS) from baseline to 1 year was not associated with either height (SDS) at 
baseline (r=-0.16, p=0.14) or change in height (SDS) during the first year of treatment (r=0.12, p=0.29). In 
contrast the change in IGF-I (SDS) was correlated with change in height (SDS) during the first year of 
treatment (r=0.46, p<0.0001).  
 
The molar ratio of IGF-I to IGFBP-3 has been suggested to reflect IGF-I bioavailability, and therefore we also 
determined IGFBP-3. However, we failed to observe correlations between changes in the IGF-I/IGFBP-3 ratio 
and changes in bioactive IGF (-0.03, p=0.8). Furthermore, the ratio correlated neither to baseline height nor 




In this cohort of SGA children treated for one year with GH, we show that the concentration of bioactive IGF 
was within the normal range in the majority of children, despite elevated total IGF-I concentrations. On the 
other hand, total IGF-I concentrations correlated better with the growth response during the first year of GH 
treatment than bioactive IGF, whereas only bioactive IGF correlated to height and weight at baseline. Insulin 
sensitivity was related to both bioactive IGF and total IGF-I concentrations as well as the binding proteins and 
growth response during the first year of treatment. To our knowledge this is the first study to explore bioactive 
IGF in a cohort of short GH treated SGA children, and we find it of interest that bioactive IGF stays within the 
normal range during the first year of treatment with GH.  
The IGF-I response in vivo is controlled by the IGFBPs that can inhibit as well as stimulate IGF-I mediated 

























IGFBP proteolysis, as cleavage of IGFBPs lower their ligand affinity, causing IGF-I to become liberated and 
hence IGF-IR accessible (20). Many proteases have been identified (MID:12466191), but the most thoroughly 
investigated enzymes as regards liberation of IGF-I and stimulation of growth include PAPP-A, which cleaves 
IGFBP-3 and IGFBP-5, and PAPPA, which cleaves IGFBP-4. The KIRA assay is a well-recognized assay for 
direct measurements of the biological active amount of IGF-I (12,13). Nevertheless, it is still controversial 
whether activation of IGF-IR in transfected cells in an artificially environment is representative of the 
endogenous activation of the IGF-IR and whether it can be translated into a biological response in cells in vivo 
(21). However, our findings of a stronger correlation between bioactive IGF and height and weight before start 
of GH treatment suggest that bioactive IGF reflects the biological active IGF-I and the endogenous secretion 
of GH. On the other hand, the IGF-I concentration was associated with change in height during the first year 
of treatment with supra-physiological GH doses which may mirror the relation between IGF-I and insulin 
sensitivity.   
 
In the current cohort the increase in bioactive IGF stayed within the normal range for most of the children 
whereas the IGF-I concentration was above the normal range in 68% of the children treated with GH for a 
year. In a Dutch of GH treated children with Prader-Willi Syndrome, almost all the children had IGF-I SDS 
levels > 2 SD, but only one child had a bioactive IGF concentration above the normal reference (22). That 
study also revealed that serum bioactive IGF concentrations correlated with neither duration of GH treatment 
nor GH dose. These findings align nicely with ours, even though the two bioassays are not strictly 
identical (15,23). Bioactive IGF has been proposed to be a better screening tool in diagnosing GHD in 
adulthood than IGF-I concentrations, showing a sensitivity of 82% for bioactive IGF vs. 62% for IGF-I 
concentration (16). Based on the same cohort of adults with GHD, another study reported that the majority of 
GHD patients had subnormal bioactive IGF levels despite normalization of IGF-I concentrations during GH 
treatment and those with normalized bioactive IGF had significantly higher concentrations of IGF-I (14). 
Furthermore, the authors concluded that bioactive IGF in large part was independent of total IGF-I, as 70-75% 
of the variation in bioactivity was unexplained by total IGF-I (24). In our study, IGF-I concentrations explained 
12% only and in conjunction the two studies indicate that the two measurement represent different entities of 
the IGF-system. Hence, these results suggest that GH dosing by titration of IGF-I concentrations is effective 
during physiological GH replacement of GHD children, but less so during pharmacological intervention with 
GH in non-GHD patients like short SGA children. 
Among the present SGA children girls were found to have significantly higher baseline levels of bioactive IGF 
(SDS) as compared to boys, whereas boys had a significantly greater change in bioactive IGF-I SDS during 
GH therapy, leading to equal levels after one year. The same pattern was not reflected in the IGF-I 
concentrations or height. These findings are in accordance with previous findings in children with PWS (15). 

























insulin between boys and girls born SGA and it may be speculated that these differences could influence timing 
of puberty in GH treated SGA children. However, opposed to our data, a former study reported that adult 
females with GHD appeared to have significantly lower levels of bioactive and total IGF-I compared to men 
(16), which is in agreement with the generally recognized fact that adult females with GHD are less sensitive 
to GH and therefore need larger doses of GH in order to normalize IGF-I levels.  
 
IGF-I mediates the growth promoting actions of GH by stimulating cell proliferation and survival. Since IGF-
I has mitogenic and anti-apoptotic effects in vitro, the role of IGF-I (and IGF-II) in cancer growth and 
development has been extensively investigated in both cellular and animal models, but the evidence of a 
cancerogenic effect in humans is weak (25). However, large epidemiological cohort studies of healthy adults 
have shown that IGF-I concentrations within the upper reference range is linked to an increased risk of cancer 
(5,6). Therefore, the long-term safety and mortality in patients treated with GH during childhood is an ongoing 
concern and this was reinforced by the first results of a large cross-Europe cohort, the Safety and 
Appropriateness of Growth Hormone treatments in Europe (SAGhE) study, published in 2012. The SAGhE 
study was established to examine mortality risk and cancer incidence in a large register study including almost 
24,000 people across Europe. The first results from the French register showed an increase all-cause mortality 
and increased mortality from bone tumors and cardiovascular disease (26). However, the following studies 
from other countries did not confirm this and the overall conclusion was that the results did not generally 
support a carcinogenic effect of GH (26–28). These findings have subsequently been supported by other studies 
(29,30) as well as in a meta-analysis (31).  Nevertheless, the uncertainty regarding IGF-I and risk of neoplasia 
has created a concern among treating physicians and generally guidelines for GH treatment of children 
recommend to keep serum IGF-I levels within the normal reference range (below 2SD) to increase safety of 
the treatment (2,8,9). However, we previously demonstrated in the NESGAS cohort that titration of the GH 
dose to keep IGF-I levels below 2SD proved less effective in terms of height gain than current dosing regimens 
for short SGA children (15). Thus, it has been speculated that some of these SGA children are less sensitive to 
IGF-I and that they may depend on continuously supra-physiological levels of IGF-I to maintain sufficient 
growth. In this context, we find it of interest that our study showed that the serum concentrations of bioactive 
IGF stayed within the normal range during high-dose GH treatment despite of elevated concentrations of IGF-
I.  
 
In conclusion, our results show for the first time that bioactive IGF levels are mainly kept within normal 
ranges despite elevated total IGF-I concentrations during one year of GH treatment of short SGA children. 
Titration of GH dose in SGA patients according to their total IGF-I concentration resulted in very low doses 
of GH and a low growth response in a previous study Further studies are needed to investigate the potential 
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Legend to figures:  
Figure 1: Bioactive IGF concentrations (µg/L), top row represents a normal reference population (grey dots), 
middle row represents baseline concentration and bottom row represents concentrations at 1 yr. Solid lines 
reflect mean +/- 2 SD, dotted lines reflect -1 SD and +1SD.  
 
Figure 2: Blue lines are boys and red lines are girls. Figure 2a: Changes in bioactive IGF during first year of 
growth hormone treatment, Figure 2b: Changes in IGF-I SDS during first year of growth hormone treatment, 
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Data are presented as Mean (SD) or median (interquartile range). Comparison between the sexes was analysed by Independent T-test or Mann-Whitney test when 
appropriate.  
 
   
       
  All children (N 
=101) 







N      
Age (years)  101 6.2 (1.7) 5.8 (1.3) 6.5 (1.8)  0.06 
Weight (SDS)  101 -3.2 (1.0) -3.2 (1.0) -3.1 (1.1)  0.30 
Height (SDS)  101 -3.4 (0.8) -3.5 (0.9) -3.4 (0.7)  0.27 
Bioactive IGF-I (µg/L)  94 1.6 (0.7) 1.8 (0.7) 1.5 (0.6)  0.03 
Bioactive IGF-I (SDS)  94 -1.2 (1.8) -0.5 (1.6) -1.6 (1.8)   0.005 
IGF-I (ng/mL) 95 81.9 (62.1 – 111.0) 91.5 (65.0 – 118.8) 79.0 (57.2 – 110.0) 0.25  
IGF-I (SDS) 95 -1.2 (1.2) -1.2 (1.1) -1.1 (1.3)  0.87 
IGFBP-3 (ng/mL)  95 2870 (2380-3475) 2870 (2580-3560) 2780 (2235-3467) 0.23  
IGFBP-3 (SDS) 95 -0.92 (-1.5 to -0.01) -0.92 (-1.37-0.12) -0.93 (-1.73 to -0.04) 0.53  
IGFBP-1 (ng/mL) 95 239 (174-320) 258 (179-350) 233 (171-294) 0.27  
       
1 year of GH therapy       
Age (years)  99 7.3 (1.6) 6.9 (1.4) 7.5 (1.7)  0.10 
Weight (SDS)  96 -2.2 (1.0) -2.2 (0.9) -2.1 (1.2)  0.70 
Height (SDS)  99 -2.4 (0.8) -2.5 (0.9) -2.4 (0.8)  0.58 
Bioactive IGF-I (µg/L) 1 year 94 2.9 (0.9) 3.0 (0.9) 2.9 (0.9)  0.60 
Bioactive IGF-I (SDS) 1 year 94 1.1 (1.4) 1.1 (1.0) 1.1 (1.6)  0.99 
IGF-I (ng/mL) 95 312.0 (225.0 – 394.0) 338.0 (282.8 – 453.5) 308.0 (217.0 – 359.5) 0.05  
IGF-I (SDS) 95 2.8 (1.5) 2.9 (1.5) 2.8 (1.5)  0.67 
IGFBP-3 (ng/mL)  95 4555 (4055-5082) 4600 (4207-5275) 4475 (3975-5000) 0.13  
IGFBP-3 (SDS) 95 1.25 (0.65-1.86) 1.17 (0.79-1.94) 1.30 (0.62-1.86) 0.77  

























          




Spearman non-parametric correlations 
*correlation is significant at the 0.05 level (two-tailed); **correlation is significant at the 0.01 level (two-tailed); ***correlation is significant at the 0.001 level (two-
tailed) 
 
All variables are baseline values except Delta Height (SDS) (height (SDS) at 1 yr – height (SDS) at baseline) 
 
       
 Bioactive 




















Bioactive IGF (SDS) 1          
IGF-I (SDS) 0.35*** 1         
IGFBP-3 (SDS) 0.62*** 0.78*** 1        
IGFBP-1 (ng/mL) -0.18 -0.15 -0.19 1       
Height (SDS) 0.29** 0.17 0.15 -0.02 1      
Delta height (SDS) -0.06 -0.22* -0.35** 0.22* 0.004 1     
Weight (SDS) 0.37*** 0.20 0.20 -0.03 0.59*** 0.04 1    
BMI (SDS) 0.18 0.10 0.11 0.10 0.16 0.24* 0.80*** 1   
Insulin sensitivity 
(HOMA-S) 
-0.29** -0.27* -0.33** 0.42*** -0.08 0.28** -0.22* -0.09 1  
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p < 0 .0 1
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